JMP Securities Begins Coverage on Context Therapeutics (NASDAQ:CNTX)

Research analysts at JMP Securities assumed coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research note issued on Wednesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $4.00 price target on the stock. JMP Securities’ price target indicates a potential upside of 266.97% from the stock’s previous close.

Several other analysts also recently commented on CNTX. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research note on Monday, September 23rd. D. Boral Capital initiated coverage on Context Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $9.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Context Therapeutics has a consensus rating of “Buy” and an average price target of $6.33.

Context Therapeutics Stock Performance

CNTX opened at $1.09 on Wednesday. The stock has a market capitalization of $81.75 million, a P/E ratio of -1.20 and a beta of 2.10. Context Therapeutics has a one year low of $0.89 and a one year high of $2.75. The business’s 50-day simple moving average is $1.56 and its 200-day simple moving average is $1.95.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, equities research analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its position in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares during the last quarter. Renaissance Technologies LLC raised its position in Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Context Therapeutics during the third quarter valued at approximately $89,000. Ally Bridge Group NY LLC grew its holdings in shares of Context Therapeutics by 159.8% in the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after acquiring an additional 1,160,281 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.